Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 18 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes. RESEARCH DESIGN AND METHODS: Randomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA1c 7–10%) allocated to one of four once-daily subcutaneous dose increase regimens: lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, and then 20 μg; n = 120), lixisenatide 1-step (10 μg for 2 weeks and then 20 μg; n = 119), placebo 2-step (n = 61), or placebo 1-step (n = 61) (placebo groups were combined for analyses). Primary end point was HbA1c change from baseline to week 12. RESULTS: Once-daily lixisenatide significantly improved HbA1c (mean baseline 8.0%) in both groups (least squares mean change vs. placebo: −0.54% for 2-step, −0.66% for 1-step; P < 0.0001). Significantly more lixisenatide patients achieved HbA1c <7.0% (52.2% 2-step, 46.5% 1-step) and ≤6.5% (31.9% 2-step, 25.4% 1-step) versus placebo (26.8% and 12.5%, respectively; P < 0.01). Lixisenatide led to marked significant improvements of 2-h postprandial glucose levels and blood glucose excursions measured during a standardized breakfast test. A significant decrease in fasting plasma glucose was observed in both lixisenatide groups versus placebo. Mean decreases in body weight (∼2 kg) were observed in all groups. The most common adverse events were gastrointestinal—nausea was the most frequent (lixisenatide 23% overall, placebo 4.1%). Symptomatic hypoglycemia occurred in 1.7% of lixisenatide and 1.6% of placebo patients, with no severe episodes. Safety/tolerability was similar for the two dose regimens. CONCLUSIONS: Once-daily lixisenatide monotherapy significantly improved glycemic control with a pronounced postprandial effect (75% reduction in glucose excursion) and was safe and well tolerated in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“None of the current DM medications associated with weight loss, including GLP-1 RAs and SGLT2is, have resulted in more than 5.6% weight loss in clinical trials, and this includes dulaglutide,765 exenatide,766 exenatide-ER,767 liraglutide 1.8 mg,768 lixisenatide,769 semaglutide 1.0 mg/week,770,771 semaglutide 1.0 mg/week added to SGLT2i,772 oral semaglutide 14 mg,773 canagliflozin,774 dapagliflozin”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [765]
In the citing paper
“The indication is to effectively reduce glycosylated hemoglobin levels in patients with T2DM by reducing fasting and postprandial blood glucose levels (61, 62).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Standards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Brown, T., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004095.pub2 · Cited by 351
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350
Ceriello, A., & Colagiuri, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02565.x · Cited by 268
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Self-citationWerner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173
GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival
Buteau, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73398-6 · Cited by 158
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 155
Self-citationMadsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 134
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004096.pub2 · Cited by 113
Morning Hyperglycemic Excursions
Monnier, L., Colette, C., Rabasa-Lhoret, R., Lapinski, H., Caubel, C., Avignon, A., & Boniface, H. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.737 · Cited by 96
Russell-Jones, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02465.x · Cited by 40
Temofonte, N., Sajan, M. P., Nimal, S., Pastoor, T., Fumero, C., Casaubon, L., Powe, J. L., Standaert, M. L., & Farese, R. V. (2009) · Diabetologia · doi:10.1007/s00125-008-1180-z · Cited by 15
Corcoy, R. (2011) · Diabetes · doi:10.2337/db10-1368 · Cited by 13
Research works printed but not linked: 3
- Distiller, 2008, Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients (Abstract), Diabetes, 57, A154
- Ratner, 2009, Post-meal pharmacodynamic profile of AVE0010, a once-daily GLP-1 receptor agonist, in patients with type 2 diabetes inadequately controlled on metformin (Abstract), Diabetologia, 52, S60
- Liu, 2009, Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment (Abstract), Diabetes, 59, A149
Cited by
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Future directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Metadata
- Authors
- Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators
- Affiliations
- Tulane University (US)
- Cardioprevent, Durango, Mexico
- Hôpital Sainte-Marguerite (FR)
- Sanofi (France) (FR)
- University of Rochester Medicine (US)
- Corresponding author
- Fonseca, Vivian A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-05-11
- Volume
- 35
- Issue
- 6
- Pages
- 1225-1231
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3357248
- OpenAlex
- W2108122035
- Cited by
- 218
- References
- 21
- Citations by year
- 2025: 5 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 19 · 2017: 27 · 2016: 23 · 2015: 20 · 2014: 31 · 2013: 39 · 2012: 5
- FWCI
- 24.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- lixisenatide, GLP-1 receptor agonists, type 2 diabetes, monotherapy, glycemic control, HbA1c, postprandial blood glucose, fasting blood glucose, weight loss, nausea, hypoglycemia, dose escalation, drug safety and tolerability, subcutaneous administration, dyslipidemia
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Adult, Aged, Aged, 80 and over, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Nausea, Peptides, United States, Blood Glucose Self-Monitoring, Body Mass Index, Treatment Outcome, Postprandial Period, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.